Phathom Pharmaceuticals (PHAT) Raw Materials (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Raw Materials data on file, last reported at $5.0 million in Q1 2026.

• Raw Materials for Q1 2026 came in at $5.0 million, up 248.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 million (up 248.79% YoY), and the FY2025 annual result was $4.1 million, up 134.88% from the prior year.
• Raw Materials climbed to $5.0 million in Q1 2026 per PHAT's latest filing, from $4.1 million in the prior quarter.
• Over five years, Raw Materials peaked at $5.0 million in Q1 2026 and troughed at $111000.0 in Q2 2023.
• A 4-year average of $1.6 million and a median of $1.2 million in 2024 frame the typical range for Raw Materials.
• The sharpest annual moves came in 2024 and 2025: Raw Materials surged 1717.12% in 2024, then sank 50.02% in 2025.
• A 4-year view of Raw Materials shows it stood at $561000.0 in 2023, then surged by 208.2% to $1.7 million in 2024, then soared by 134.88% to $4.1 million in 2025, then rose by 23.76% to $5.0 million in 2026.
• Business Quant data shows PHAT's Raw Materials at $5.0 million in Q1 2026, $4.1 million in Q4 2025, and $1.0 million in Q3 2025.